ELF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ELF is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive fundamental catalysts from Rhode and recent revenue growth, but the current setup is mixed: analysts are cutting targets broadly, insiders are selling aggressively, and the technical trend is still under a bearish moving-average structure. I would not call this an immediate buy; the better call is to hold and wait for either a cleaner technical reversal or a more attractive entry.
Price is 57.52, slightly above the prior close, with the market closed. Momentum is constructive short term: MACD histogram is positive and expanding, and RSI at 61.62 shows mild strength without being overbought. However, the broader trend is still bearish because SMA_200 > SMA_20 > SMA_5, which means the longer-term structure is not yet fully repaired. Price is trading just under the first resistance zone (R1 58.511) and above pivot 54.674, so near-term upside exists, but the stock is not in a clear long-term uptrend yet. Similar candlestick pattern analysis suggests modest upside probability over the next month, but not enough to override the weak trend structure.
Recent news is supportive on the growth side: Rhode contributed meaningfully to Q4 revenue, and the company reported 35% year-over-year revenue growth in the latest quarter shown. Management also projected fiscal 2027 revenue growth of 14% to 17%, which keeps a long-term growth narrative intact. The brand campaign news for Naturium also signals active brand-level marketing momentum in the category. Technical momentum is improving in the short term, and options sentiment is mildly bullish.
Analysts have been cutting price targets across the board, including large reductions from B. Riley, Piper Sandler, Canaccord, Deutsche Bank, Morgan Stanley, Baird, TD Cowen, JPMorgan, Citi, and BofA. The tone is increasingly cautious because of slowing core Elf Cosmetics consumption, tougher comps, and margin/reinvestment concerns. Insider selling is a major negative: insiders are selling and the selling amount increased 3611.29% over the last month. Hedge funds are neutral, and there is no recent congress trading data to add a positive catalyst. The bearish moving-average structure also shows the stock is still not fully trending upward on a long-term basis.
The latest quarter cited is Q4 2023. e.l.f. Beauty reported $449.3 million in revenue, up 35% year over year, which is a strong growth rate. Rhode was a major contributor with $113 million in revenue and 80% annual sales growth. The downside was profitability: adjusted EPS fell 59% because of higher marketing investments. That means growth remains strong, but earnings quality and margin pressure are still concerns. For a long-term beginner investor, the business is growing, but not at a clean enough earnings inflection to justify an aggressive immediate buy.
Wall Street is mixed-to-cautious. Several firms still rate the stock Buy/Outperform/Overweight, but price targets have been cut sharply, signaling reduced conviction in the near-term upside. The latest trend shows a downgrade from Morgan Stanley to Equal Weight and a Hold from Deutsche Bank, while other firms like B. Riley and Piper Sandler kept positive or neutral ratings but still lowered targets materially. Pros: strong brand growth, Rhode momentum, and continued revenue expansion. Cons: slowing core consumption, tougher competition, margin pressure, and valuation compression. Overall, the pros view is no longer strong enough to support an immediate buy for this investor profile.
